Estradiol benzoate butyrate/algestone acetophenide
 | |
 | |
| Combination of | |
|---|---|
| Estradiol benzoate butyrate | Estrogen |
| Algestone acetophenide | Progestogen |
| Clinical data | |
| Trade names | Neolutin N, Redimen, Soluna, Unijab |
| Other names | Estradiol benzoate butyrate/dihydroxyprogesterone acetophenide; EBB/DHPA; Unimens |
| Routes of administration | Intramuscular injection |
Estradiol benzoate butyrate/algestone acetophenide, also known as estradiol benzoate butyrate/dihydroxyprogesterone acetophenide (EBB/DHPA) and sold under the brand names Neolutin N, Redimen, Soluna, and Unijab, is a form of combined injectable birth control which is used in Peru and Singapore.[1][2][3][4][5][6] It contains estradiol benzoate butyrate (EBB), an estrogen, and algestone acetophenide (dihydroxyprogesterone acetophenide; DHPA), a progestin.[2][3] The medication is given once per month by injection into muscle.[3]
Medical uses
[edit]EBB/DHPA is used as a once-a-month combined injectable contraceptive to prevent pregnancy in women.[1][2][3]
Available forms
[edit]EBB/DHPA contains 10 mg estradiol benzoate butyrate (EBB), an estrogen, and 150 mg algestone acetophenide (dihydroxyprogesterone acetophenide; DHPA), a progestin.[2][3]
Pharmacology
[edit]Pharmacodynamics
[edit]EBB/DHPA has been said to have relatively weak estrogenic activity and has been described as "progestogen-dominant".[1]
Pharmacokinetics
[edit]EBB is said to have a shorter duration than estradiol enantate of about 3 weeks.[7] EBB/DHPA was developed because it was thought that the duration of EBB would be more suitable for use as a once-monthly combined injectable contraceptive than estradiol enantate in estradiol enantate/algestone acetophenide.[7]
Society and culture
[edit]Brand names
[edit]EBB/DHPA is marketed under the brand names Neolutin N, Redimen, Soluna, and Unijab.[1][2][3][4][5][6][8] It was originally developed under the tentative brand name Unimens, but ultimately was not marketed under this particular brand name.[1][7][9][10][11]
Availability
[edit]EBB/DHPA is available only in Peru and Singapore.[2][3]
See also
[edit]- Combined injectable birth control § Available forms
- Estradiol enantate/algestone acetophenide
- List of combined sex-hormonal preparations
References
[edit]- ^ a b c d e Toppozada M (June 1977). "The clinical use of monthly injectable contraceptive preparations". Obstet Gynecol Surv. 32 (6): 335–47. doi:10.1097/00006254-197706000-00001. PMID 865726.
- ^ a b c d e f IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 433, 467. ISBN 978-92-832-1291-1.
- ^ a b c d e f g IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; International Agency for Research on Cancer (1 January 1999). Hormonal Contraception and Post-menopausal Hormonal Therapy (PDF). IARC. p. 65. ISBN 978-92-832-1272-0. Archived from the original (PDF) on 28 August 2021. Retrieved 16 September 2018.
- ^ a b "Farmaco SOLUNA 150 + 10 registrado en Perú".
- ^ a b "Unijab Dosage & Drug Information | MIMS Singapore".
- ^ a b "SOLUNA". www.corporacionmisalud.com. Archived from the original on 2014-10-05.
- ^ a b c Mokhtar K. Toppozada (1983). "Monthly Injectable Contraceptives". In Alfredo Goldsmith; Mokhtar Toppozada (eds.). Long-Acting Contraception. pp. 93–103. OCLC 35018604.
- ^ "Archived copy". Archived from the original on 2019-02-25. Retrieved 2019-02-25.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ Elsayed Saad Eldin Hafez (1980). Human reproduction: conception and contraception. Harper and Row. ISBN 978-0-06-141066-6.
- ^ Newton JR, D'arcangues C, Hall PE (1994). "A review of "once-a-month" combined injectable contraceptives". J Obstet Gynaecol (Lahore). 4 Suppl 1: S1–34. doi:10.3109/01443619409027641. PMID 12290848.
- ^ Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
